Erratum



Erratum to "Intranasal Delivery of Chitosan Nanoparticles for Migraine Therapy" [Sci Pharm. 2013; 81: 843-854]

Neha Gulati * 1, Upendra Nagaich 1, Shubhini A. Saraf 2

¹ Department of Pharmaceutics, School of Pharmacy, Bharat Institute of Technology, Meerut, UP, India. ² School of Biosciences and Biotechnology, Babasaheb Bhimrao Ambedkar University, Lucknow, India.

Sci Pharm. 2013; 81: 1167–1169 doi:10.3797/scipharm.1208-18err

Published: October 6th 2013 Received: October 4th 2013

Accepted: October 6th 2013

This article is available from: http://dx.doi.org/10.3797/scipharm.1208-18err

© Gulati et al.; licensee Österreichische Apotheker-Verlagsgesellschaft m. b. H., Vienna, Austria.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

This is an erratum to the article 'Intranasal Delivery of Chitosan Nanoparticles for Migraine Therapy' [Sci Pharm. 2013; 81: 843–854]. Figures 1–3 are added.

Keywords

Erratum • Sci Pharm. 2013; 81: 843-854

Unfortunately, all three figures were missing in the published article [1]. The authors and the editorial office are very sorry for this error and for any inconvenience this caused.

^{*} Corresponding author. E-mail: ngulati88@gmail.com (N. Gulati)




Fig. 1. SEM Photomicrograph of sumatriptan succinate loaded Chitosan nanoparticles




Fig. 2. Particle size and Entrapment Efficiency of nine formulations




Fig. 3. In vitro drug release profiles of sumatriptan loaded chitosan nanoparticles

Authors' Statement

Competing Interests

The authors declare no conflict of interest.

Reference

[1] Gulati N, Nagaich U, Saraf SA. Intranasal Delivery of Chitosan Nanoparticles for Migraine Therapy. Sci Pharm. 2013; 81: 843–854. http://dx.doi.org/10.3797/scipharm.1208-18